

Market Outlook

The Nifty 50 closed at 25,959, down 0.41% for the day as the index struggled to hold intraday recoveries. On the derivatives front, the 26,100 strike carries the highest Call OI, marking a strong supply zone and key upside barrier. Support has now shifted to 25,900, where notable Put OI addition indicates firm defence by market participants. With 26,050 acting as immediate resistance, the index is moving within a tight range, and a sustained move above this level may trigger short covering, while a breakdown below 25,900 could lead to further selling pressure and tilt momentum in favour of the bears.

Key Indices Update

INDEX	CLOSE	CHANGE (%)
NIFTY	25959	-0.41
SENSEX	84900	-0.38
BANKNIFTY	58835	-0.05
INDIA VIX	13.23	-2.90

FII's STATISTICS


FII's F&O Data

Sector	Buy/Sell	Change in OI
Index Futures	1566.48	3.00%
Index Options	-5908.92	16.63%
Stock Futures	6169.13	0.10%
Stock Options	-3732.77	-20.21%

FII's & DII's Cash Segment (Rs. In Crore)

Category	Amount	MTD	YTD
FII	-4171.75	-18012	-128232
DII	4512.87	58833	501283

FII's Activity in Index Future



Amt in Crores


NIFTY 50 HIGH DELIVERY STOCKS

SYMBOL	DELIVERABLE QTY	CHG IN DLY RATIO VS PREV DAY	% CHG IN TRD QTY OVER PREV DAY
POWERGRID	43123324	8.87	284.74
ETERNAL	27147867	0.66	209.69
HDFCBANK	23158827	4.58	84.02
TATASTEEL	21487853	15.58	9.82
BEL	14424438	5.12	182.27
RELIANCE	12818848	15.28	91.72
WIPRO	12180030	12.5	257.31
ONGC	11987338	-0.33	109.18
INFY	11831028	-9.12	109.77
NTPC	10791382	20.65	123.36


NIFTY

Nifty	25996.40
OI (In contracts)	279611
CHANGE IN OI (%)	1.90
PRICE CHANGE (%)	-0.30
IMPLICATION	SHORT BUILDUP

NIFTY (CLOSE VS OI)



NIFTY OPTION CHAIN




Long Buildup

Symbol	Price	Price %	OI	OI %
FORTIS	921.6	0.10	22029	19.80
KEI	4109.2	0.80	6613	13.10
RVNL	318.85	1.80	32271	10.70
NYKAA	270.84	0.80	20767	8.60
HCLTECH	1611.4	0.10	50630	7.40


BANKNIFTY

Banknifty	58871.80
OI (In contracts)	59724
CHANGE IN OI (%)	-4.80
PRICE CHANGE (%)	0.00
IMPLICATION	NEUTRAL

BANKNIFTY (CLOSE VS OI)



BANKNIFTY OPTION CHAIN



Short Buildup

Symbol	Price	Price %	OI	OI %
POWERINDIA	21375	-0.80	3975	15.10
PPLPHARMA	186.67	-0.60	10623	10.40
OIL	420.15	-1.30	9258	8.80
PAYTM	1259.6	-0.50	34016	7.30
PRESTIGE	1630.7	-3.30	8685	6.90

Top 10 High PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
PETRONET	17577000	15653400	1.12
VOLTAS	3963375	3592125	1.1
HEROMOTOCO	2889000	2665350	1.08
CANBK	119043000	119805750	0.99
EICHERMOT	2612550	2707725	0.96
PERSISTENT	930300	969600	0.96
FEDERALBNK	38700000	42685000	0.91
AUBANK	5511000	6198000	0.89
BPCL	16542600	19092325	0.87
SAIL	36960800	42314100	0.87

Top 10 Low PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
KAYNES	1000300	2974500	0.34
BOSCHLTD	58400	166725	0.35
TATASTEEL	109318000	308572000	0.35
PATANJALI	3280500	8573400	0.38
PPLPHARMA	6330625	16678125	0.38
SUPREMEIND	750400	1927975	0.39
ADANIGREEN	7189800	18003000	0.4
ONGC	23296500	57800250	0.4
TMPV	32097600	80423200	0.4
SHREECEM	54450	132225	0.41

NIFTY 50 SUPPORT-RESISTANCE LEVELS

SYMBOL	R1	R2	PP	S1	S2
ADANIENT	2427	2452	2411	2386	2370
ADANIPTS	1491	1498	1481	1474	1463
APOLLOHOSP	7402	7457	7363	7309	7270
ASIANPAINT	2893	2908	2877	2862	2846
AXISBANK	1284	1298	1274	1259	1249
BAJAJ-AUTO	9108	9188	8981	8901	8775
BAJAJFINSV	2053	2075	2039	2017	2003
BAJFINANCE	1005	1016	999	988	981
BEL	412	420	407	399	394
BHARTIARTL	2161	2176	2146	2132	2117
CIPLA	1521	1536	1511	1496	1486
COALINDIA	377	381	375	370	368
DRREDDY	1255	1281	1238	1211	1194
EICHERMOT	7285	7333	7208	7160	7084
ETERNAL	305	308	300	297	292
GRASIM	2727	2764	2705	2668	2645
HCLTECH	1633	1655	1620	1598	1584
HDFCBANK	1009	1018	1002	994	987
HDFCLIFE	771	781	764	753	747
HINDALCO	785	796	778	768	761
HINDUNILVR	2447	2463	2432	2416	2401
ICICIBANK	1375	1382	1369	1361	1355
INDIGO	5906	5997	5842	5751	5687
INFY	1577	1601	1563	1540	1526
ITC	408	412	405	402	399

SYMBOL	R1	R2	PP	S1	S2
JIOFIN	303	306	301	298	297
JSWSTEEL	1133	1157	1118	1094	1079
KOTAKBANK	2101	2114	2090	2076	2065
LT	4033	4051	4019	4000	3986
M&M	3733	3773	3704	3663	3634
MARUTI	16056	16144	15999	15911	15854
MAXHEALTH	1175	1197	1163	1141	1129
NESTLEIND	1284	1297	1272	1258	1246
NTPC	326	329	324	322	320
ONGC	247	248	246	244	243
POWERGRID	278	281	275	273	269
RELIANCE	1549	1560	1541	1531	1523
SBILIFE	2021	2029	2013	2005	1996
SBIN	975	980	971	966	961
SHRIRAMFIN	838	847	830	821	813
SUNPHARMA	1783	1789	1775	1769	1762
TATACONSUM	1194	1203	1183	1174	1163
TATASTEEL	168	170	166	164	163
TCS	3212	3278	3172	3106	3066
TECHM	1518	1540	1491	1469	1442
TITAN	3916	3956	3893	3853	3830
TMPV	363	366	360	356	353
TRENT	4349	4394	4324	4279	4254
ULTRACEMCO	11702	11824	11628	11506	11432
WIPRO	250	251	248	247	245

Research Team

Name	Email ID
<i>Ajit Mishra</i>	ajit.mishra@religare.com
<i>Abhijeet Banerjee</i>	abhijeet.banerjee@religare.com
<i>Gaurav Sharma</i>	gauravsharma2@religare.com
<i>Ashwani Harit</i>	ashwani.harit@religare.com
<i>Divya Parmar</i>	divya.parmar@religare.com
<i>Rajan Gupta</i>	rajan.gupta1@religare.com
<i>Vivek Chandra</i>	vivek.chandra@religare.com
<i>Himanshu Gupta</i>	himanshu.gupta1@religare.com
<i>Vishvajeet Singh</i>	vishvajeet.singh1@religare.com

Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes:

..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results